Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Saved in:
| Title: | Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. |
|---|---|
| Authors: | Motzer RJ; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. motzerr@mskcc.org., Robbins PB; Translational Oncology, Pfizer, San Diego, CA, USA., Powles T; Department of Genitourinary Oncology, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew's Hospital, London, UK., Albiges L; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France., Haanen JB; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Larkin J; Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, UK., Mu XJ; Computational Biology, Pfizer, San Diego, CA, USA., Ching KA; Computational Biology, Pfizer, San Diego, CA, USA., Uemura M; Graduate School of Medicine, Osaka University Hospital, Osaka, Japan., Pal SK; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Alekseev B; Deputy Director for Science, Moscow Scientific Research Oncology Institute, Moscow, Russian Federation., Gravis G; Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France., Campbell MT; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Penkov K; Private Medical Institution, Euromedservice, St. Petersburg, Russian Federation., Lee JL; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea., Hariharan S; Oncology, Pfizer, New York, NY, USA., Wang X; Computational Biology, Pfizer, San Diego, CA, USA.; Lyell Immunopharma, South San Francisco, CA, USA., Zhang W; Biostatistics, Pfizer, Cambridge, MA, USA.; Jounce Therapeutics, Cambridge, MA, USA., Wang J; Biostatistics, Pfizer, Cambridge, MA, USA., Chudnovsky A; Oncology, Pfizer, Cambridge, MA, USA.; Ipsen, Cambridge, MA, USA., di Pietro A; Immuno-Oncology, Pfizer, Milan, Italy., Donahue AC; Translational Oncology, Pfizer, La Jolla, CA, USA., Choueiri TK; Department of Medical Oncology, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA. toni_choueiri@dfci.harvard.edu. |
| Source: | Nature medicine [Nat Med] 2020 Nov; Vol. 26 (11), pp. 1733-1741. Date of Electronic Publication: 2020 Sep 07. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
